Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 1.00 |
| ▸ | PPARG | P37231 | 8/20 | 0.55 |
| ▸ | PPARD | Q03181 | 3/20 | 0.55 |
| ▸ | PPARA | Q07869 | 3/20 | 0.55 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7257775 | 0.82 | CA2 (0.69) | CA2PPARGPPARDPPARADDB1 | |
| SCHEMBL3066557 | 0.80 | CA2 (0.67) | CA2PPARGPPARDPPARADDB1 | |
| SCHEMBL9798942 | 0.80 | CA2 (0.67) | CA2PPARGPPARDPPARADDB1 | |
| SCHEMBL8544891 | 0.80 | CA2 (0.67) | CA2PPARGPPARDPPARADDB1 | |
| SCHEMBL14622471 | 0.80 | CA2 (0.67) | CA2PPARGPPARDPPARADDB1 | |
| SCHEMBL22623633 | 0.78 | CA2 (0.64) | CA2PPARGPPARDPPARADDB1 | |
| SCHEMBL5209389 | 0.77 | CA2 (0.60) | CA2PPARGPPARDPPARAHPGD | |
| SCHEMBL3626456 | 0.77 | CA2 (0.62) | CA2KDM4EHPGDUSP2ESR1 | |
| SCHEMBL8543290 | 0.77 | CA2 (0.61) | CA2PPARGPPARDPPARADDB1 | |
| SCHEMBL5209383 | 0.76 | CA2 (0.59) | CA2PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152746-A1 | Treatment of scarring and related conditions using ppar-gamma activators | ARACHNOVA THERAPEUTICS LTD. (JE) | 2004-08-05 | — | — | US | claimed |
| EP-1385516-A1 | THE TREATMENT OF SCARRING AND RELATED CONDITIONS USING PPAR-GAMMA ACTIVATORS | Arachnova Therapeutics Ltd. (GB) | 2004-02-04 | — | — | EP | claimed |
| WO-2002087576-A1 | THE TREATMENT OF SCARRING AND RELATED CONDITIONS USING PPAR-GAMMA ACTIVATORS | ARACHNOVA THERAPEUTICS LTD. (GB) | 2002-11-07 | — | — | WO | claimed |
| CN-101463031-B | Indazole and tetrahydrochysene indazole compounds, and preparation, pharmaceutical composition and use thereof | INST MATERIA MEDICA CAMS | 2014-02-12 | — | — | CN | disclosed |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-7262318-B2 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20030170865-A1 | Novel polypeptide of protein p140 and DNAs encoding it | ONO PHARMACEUTICAL CO., LTD. | 2003-09-11 | — | — | US | disclosed |
| EP-0659883-B1 | Protein p140 and DNA encoding it | ONO PHARMACEUTICAL CO (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-6432913-B1 | ANTIDIABETIC AGENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-08-13 | — | — | US | disclosed |
| US-6303320-B1 | SCREENING FOR MODULATOR OF GLUCOSE USE; ADMINISTER MODULATOR TO CELLS IN VITRO, CULTURE CELLS, COMPARE PHOSPHORYLATED PROTEIN WITH GLUCOSE USE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-10-16 | — | — | US | disclosed |
| EP-0527232-B1 | THIAZOLIDINE-2,4-DIONE DERIVATIVE, SALT THEREOF, AND PRODUCTION THEREOF | KYORIN SEIYAKU KK (JP) | 1998-09-23 | — | — | EP | disclosed |
| EP-0319189-B1 | THIAZOLIDINEDIONES AS HYPOGLYCEMIC AND ANTI-ATHEROSCLEROSIS AGENTS | PFIZER INC. (US) | 1992-06-10 | — | — | EP | disclosed |
| WO-1992007839-A1 | THIAZOLIDINEDIONE DERIVATIVES | BEECHAM GROUP PLC (GB) | 1992-05-14 | — | — | WO | disclosed |
| EP-0207605-B1 | HYPOGLYCEMIC THIAZOLIDINEDIONES | PFIZER INC. (US) | 1990-02-07 | — | — | EP | disclosed |
| EP-0319189-A1 | Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents | PFIZER INC. (US) | 1989-06-07 | — | — | EP | disclosed |
| US-4791125-A | Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents | PFIZER INC. (US) | 1988-12-13 | — | — | US | disclosed |
| US-4738972-A | Hypoglycemic thiazolidinediones | PFIZER INC. (US) | 1988-04-19 | — | — | US | disclosed |
| US-4703052-A | Hypoglycemic thiazolidinediones | PFIZER INC. (US) | 1987-10-27 | — | — | US | disclosed |
| EP-0207605-A1 | Hypoglycemic thiazolidinediones | PFIZER INC. (US) | 1987-01-07 | — | — | EP | disclosed |
| WO-1986007056-A1 | HYPOGLYCEMIC THIAZOLIDINEDIONES | PFIZER INC. (US) | 1986-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152746-A1 | Treatment of scarring and related conditions using ppar-gamma activators | PPARA, PPARD, PPARG | CA2 4837/4885PPARG 3/4885PPARD 2/4885 |
| US-20030170865-A1 | Novel polypeptide of protein p140 and DNAs encoding it | IAPP, FAM20C, GID4 | CA2 3897/4885PPARG 4805/4885PPARD 4519/4885 |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | CA2 4864/4885PPARG 2/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.